[go: up one dir, main page]

FR2939045B1 - Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique - Google Patents

Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique

Info

Publication number
FR2939045B1
FR2939045B1 FR0806785A FR0806785A FR2939045B1 FR 2939045 B1 FR2939045 B1 FR 2939045B1 FR 0806785 A FR0806785 A FR 0806785A FR 0806785 A FR0806785 A FR 0806785A FR 2939045 B1 FR2939045 B1 FR 2939045B1
Authority
FR
France
Prior art keywords
compositions
pharmaceutical
preventing
methods
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0806785A
Other languages
English (en)
Other versions
FR2939045A1 (fr
Inventor
Daniel Sincholle
Claude Bonne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0806785A priority Critical patent/FR2939045B1/fr
Publication of FR2939045A1 publication Critical patent/FR2939045A1/fr
Application granted granted Critical
Publication of FR2939045B1 publication Critical patent/FR2939045B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/52Juglandaceae (Walnut family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • A61K36/742Coffea, e.g. coffee
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques ou des compléments alimentaires dotées de propriétés anti-inflammatoires qui comprennent des polyphénols antioxydants capables de freiner l'expression de cytokines pro-inflammatoires induites par les endotoxines bactériennes et de s'opposer à la formation des eicosanoïdes médiateurs de l'inflammation. Ces compositions sont utiles pour traiter l'inflammation colique et l'endotoxémie métabolique responsables de surpoids et de l'obésité. En particulier, l'invention concerne des compositions pour administration orale fondées sur l'association d'une part d'extraits végétaux anti-inflammatoires riches en flavono-lignanes, en dérivés de l'acide caféique, en resvératrol, et d'autre part de fibres alimentaires, polymères de fructose ou de xylose, à effet bifodogène et permettant de restaurer l'homéostasie intestinale.
FR0806785A 2008-12-02 2008-12-02 Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique Active FR2939045B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0806785A FR2939045B1 (fr) 2008-12-02 2008-12-02 Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806785A FR2939045B1 (fr) 2008-12-02 2008-12-02 Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique

Publications (2)

Publication Number Publication Date
FR2939045A1 FR2939045A1 (fr) 2010-06-04
FR2939045B1 true FR2939045B1 (fr) 2010-12-31

Family

ID=40897364

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0806785A Active FR2939045B1 (fr) 2008-12-02 2008-12-02 Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique

Country Status (1)

Country Link
FR (1) FR2939045B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3094612B1 (fr) * 2019-04-05 2022-08-19 Laboratoires Iphym Composition comprenant un extrait de cafe vert et une Superoxyde dismutase (SOD)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442602A1 (fr) * 2000-12-18 2002-08-01 Probio Health, Llc Composes probiotiques obtenus a partir d'une souche de lactobacillus casei (ke01)
PT1750651T (pt) * 2003-12-18 2018-02-16 Nestec Sa Composição para melhorar a saúde da pele, cabelo e pelo contendo flavanonas
US7125963B2 (en) * 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
DK2233127T3 (da) * 2004-03-17 2020-08-24 Stada Arzneimittel Ag Anvendelse af antioxidanter til fremstilling af en farmaceutisk eller kosmetisk sammensætning for at beskytte huden mod skader som følge af infrarød stråling
US20070065396A1 (en) * 2005-09-21 2007-03-22 Tracie Martyn International, Llc Topical macqui berry formulation
WO2008143182A1 (fr) * 2007-05-17 2008-11-27 Kaneka Corporation Composition contenant un polyphénol dérivé de la réglisse

Also Published As

Publication number Publication date
FR2939045A1 (fr) 2010-06-04

Similar Documents

Publication Publication Date Title
Balakumar et al. Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it?
MX343321B (es) Composicion para ser usada en la prevencion de infecciones agudas del tracto respiratorio y/o para aliviar los sintomas de dichas infecciones.
MY158504A (en) Fatty acid niacin conjugates and their uses
PH12013501319A1 (en) Fatty acid acetylated salicylates and their uses
Huang et al. Antiadhesion and anti-inflammation effects of noni (Morinda citrifolia) fruit extracts on AGS cells during Helicobacter pylori infection
CO6410310A2 (es) Composiciones que comprenden componentes probióticos y prebióticos y sales minerales, con lactoferrina
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
WO2007117706A3 (fr) Forme pharmaceutique solide par voie orale contenant un activateur
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
MA33075B1 (fr) Composition destinee a la regulation du metabolism des lipides
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
MA32931B1 (fr) Compositions antimicrobiennes
EP2014295A3 (fr) Compositions topiques pour la prévention et le traitement d'états inflammatoires et/ou infectieux de la région génitale
Bhandari et al. Naringenin and its nanocarriers as potential phytotherapy for autism spectrum disorders
WO2012049222A3 (fr) Nouvelles compositions contenant des acides gras oméga-3 et oméga-6 et leurs utilisations
WO2010045577A3 (fr) Extraits de curcuma et leurs procédés d'utilisation
WO2011062436A3 (fr) Composition permettant d'améliorer la circulation sanguine, contenant un extrait de lindera obtusiloba formant ingrédient actif
ECSP13012798A (es) Método para inhibir patógenos usando una composición nutricional
FR2939045B1 (fr) Compositions pharmaceutiques et nutritionnelles et methode utile pour prevenir et traiter l'inflammation colique et l'endotoxemie metabolique
WO2009019307A3 (fr) Compositions à base de calcitonine orale et leurs applications
EA201071377A1 (ru) Композиции на основе растений и их применение
Singal et al. Reversal of LPS‐induced immobility in mice by green tea polyphenols: possible COX‐2 mechanism

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17